A small percentage (1–2%) of newly diagnosed PCa may present as de novo AR− neuroendocrine PCa (NEPC), which is most frequently associated with mutations or loss of tumor suppressor genes RB1 and/or TP53. The gene discussed is TP53; the disease is posterior cortical atrophy.